SW
CNCE

SVB Wealth’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

SVB Wealth’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-381,326
Closed -$1.25M – 978
2021
Q3 		$1.25M Hold
381,326
– – 0.02% 345
2021
Q2 		$1.61M Hold
381,326
– – 0.02% 292
2021
Q1 		$1.9M Hold
381,326
– – 0.03% 246
2020
Q4 		$4.82M Hold
381,326
– – 0.07% 162
2020
Q3 		$3.75M Hold
381,326
– – 0.06% 169
2020
Q2 		$3.79M Buy
+381,326
New +$3.66M 0.07% 155

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SVB Wealth's CNCE Position: Q4 2021 in Review

SVB Wealth sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2021, closing a stake of 381,326 shares — an estimated $1.25M sold.

SVB Wealth first reported a position in CNCE in Q2 2020 and held it in 6 quarters. The position peaked at $4.82M in Q4 2020. 52 funds tracked by Wall St. Rank hold CNCE as of Q4 2021.

  • SVB Wealth reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • SVB Wealth sold 381,326 Concert Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.25M.
  • SVB Wealth first reported a position in Concert Pharmaceuticals, Inc. in Q2 2020 and held it in 6 quarters.
  • SVB Wealth's Concert Pharmaceuticals, Inc. position peaked at $4.82M in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2021.

Based on SVB Wealth's 13F filing for Q4 2021, filed 15 Feb 2022.